279 related articles for article (PubMed ID: 33380880)
21. [Current status of diagnosis and treatment of chronic lymphocytic leukemia in China: A national multicenter survey research].
Xu W; Yi SH; Feng R; Wang X; Jin J; Mi JQ; Ding KY; Yang W; Niu T; Wang SY; Zhou KS; Peng HL; Huang L; Liu LH; Ma J; Luo J; Su LP; Bai O; Liu L; Li F; He PC; Zeng Y; Gao D; Jiang M; Wang JS; Yao HX; Qiu LG; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):380-387. PubMed ID: 37550187
[No Abstract] [Full Text] [Related]
22. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
[TBL] [Abstract][Full Text] [Related]
23. Targeting Bruton's Tyrosine Kinase in CLL.
Ahn IE; Brown JR
Front Immunol; 2021; 12():687458. PubMed ID: 34248972
[TBL] [Abstract][Full Text] [Related]
24. How We Manage Patients with Indolent B-Cell Malignancies on Bruton's Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists.
Nixon S; Duquette D; Doucette S; Larouche JF
Curr Oncol; 2023 Apr; 30(4):4222-4245. PubMed ID: 37185435
[TBL] [Abstract][Full Text] [Related]
25. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
26. Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy.
Roeker LE; Thompson M; Mato AR
Drugs; 2022 Feb; 82(2):133-143. PubMed ID: 34932207
[TBL] [Abstract][Full Text] [Related]
27. Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia.
Lipsky AH; Lamanna N
Cancer; 2023 Jan; 129(1):18-31. PubMed ID: 36326285
[TBL] [Abstract][Full Text] [Related]
28. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Sun C; Nierman P; Kendall EK; Cheung J; Gulrajani M; Herman SEM; Pleyer C; Ahn IE; Stetler-Stevenson M; Yuan CM; Maric I; Gaglione EM; Harris HM; Pittaluga S; Wang MH; Patel P; Farooqui MZH; Izumi R; Hamdy A; Covey T; Wiestner A
Blood; 2020 Jul; 136(1):93-105. PubMed ID: 32202637
[TBL] [Abstract][Full Text] [Related]
29. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
[TBL] [Abstract][Full Text] [Related]
30. [Reaserch Advance on Inhibitor Targeting at the B-Cell Receptor Pathway in Chronic Lymphocytic Leukemia --Review].
Ji TT; Chen QN; Tao SD; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):708-712. PubMed ID: 32319422
[TBL] [Abstract][Full Text] [Related]
31. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Gozzetti A; Candi V; Brambilla CZ; Papini G; Fabbri A; Bocchia M
Anticancer Agents Med Chem; 2017; 17(8):1040-1045. PubMed ID: 27697038
[TBL] [Abstract][Full Text] [Related]
32. Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor.
Alkharabsheh O; Alsayed A; Morlote DM; Mehta A
Curr Oncol; 2021 Feb; 28(1):837-841. PubMed ID: 33567487
[TBL] [Abstract][Full Text] [Related]
33. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Thompson PA; Burger JA
Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
[TBL] [Abstract][Full Text] [Related]
34. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
35. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
Sharma S; Galanina N; Guo A; Lee J; Kadri S; Van Slambrouck C; Long B; Wang W; Ming M; Furtado LV; Segal JP; Stock W; Venkataraman G; Tang WJ; Lu P; Wang YL
Oncotarget; 2016 Oct; 7(42):68833-68841. PubMed ID: 27626698
[TBL] [Abstract][Full Text] [Related]
36. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.
Zhang D; Harris HM; Chen J; Judy J; James G; Kelly A; McIntosh J; Tenn-McClellan A; Ambing E; Tan YS; Lu H; Gajewski S; Clifton MC; Yung S; Robbins DW; Pirooznia M; Skånland SS; Gaglione E; Mhibik M; Underbayev C; Ahn IE; Sun C; Herman SEM; Noviski M; Wiestner A
Blood; 2023 Mar; 141(13):1584-1596. PubMed ID: 36375120
[TBL] [Abstract][Full Text] [Related]
37. BTK Inhibitors and Chemoimmunotherapy for CLL.
Thompson P
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S22-S24. PubMed ID: 32862855
[No Abstract] [Full Text] [Related]
38. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Byrd JC; Wierda WG; Schuh A; Devereux S; Chaves JM; Brown JR; Hillmen P; Martin P; Awan FT; Stephens DM; Ghia P; Barrientos J; Pagel JM; Woyach JA; Burke K; Covey T; Gulrajani M; Hamdy A; Izumi R; Frigault MM; Patel P; Rothbaum W; Wang MH; O'Brien S; Furman RR
Blood; 2020 Apr; 135(15):1204-1213. PubMed ID: 31876911
[TBL] [Abstract][Full Text] [Related]
39. Selecting initial therapy in CLL.
Ahn IE; Brown JR
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):323-328. PubMed ID: 36485152
[TBL] [Abstract][Full Text] [Related]
40. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]